Immunomedics Company Profile (NASDAQ:IMMU)

About Immunomedics

Immunomedics logoImmunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: IMMU
  • CUSIP: 45290710
Key Metrics:
  • Previous Close: $5.34
  • 50 Day Moving Average: $4.33
  • 200 Day Moving Average: $3.29
  • 52-Week Range: $1.91 - $5.89
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 267.00
  • P/E Growth: 0.00
  • Market Cap: $566.46M
  • Outstanding Shares: 106,079,000
  • Beta: 1.68
Profitability:
  • Net Margins: -2,385.59%
  • Return on Assets: -116.00%
Debt:
  • Debt-to-Equity Ratio: -1.30%
  • Current Ratio: 1.69%
  • Quick Ratio: 1.67%
Additional Links:
Companies Related to Immunomedics:

Analyst Ratings

Consensus Ratings for Immunomedics (NASDAQ:IMMU) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $5.50 (3.00% upside)

Analysts' Ratings History for Immunomedics (NASDAQ:IMMU)
Show:
DateFirmActionRatingPrice TargetDetails
10/6/2016Jefferies Group LLCInitiated CoverageBuy$5.00 -> $5.50View Rating Details
6/21/2016Wells Fargo & CompanyDowngradeOutperform -> Market PerformView Rating Details
7/29/2015Oppenheimer Holdings, Inc.Reiterated RatingOutperformView Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Immunomedics (NASDAQ:IMMU)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/9/2017        
8/17/2016Q416($0.11)($0.17)$1.20 millionViewListenView Earnings Details
5/4/2016Q3($0.13)($0.15)$2.13 millionViewN/AView Earnings Details
2/3/2016Q216($0.14)($0.15)$1.23 millionViewN/AView Earnings Details
11/5/2015Q116($0.14)($0.16)$1.23 millionViewN/AView Earnings Details
8/19/2015Q415($0.13)($0.13)$1.13 million$2.40 millionViewListenView Earnings Details
5/6/2015($0.13)($0.13)ViewN/AView Earnings Details
2/5/2015Q215($0.13)($0.12)$1.38 millionViewN/AView Earnings Details
11/5/2014($0.12)($0.13)ViewN/AView Earnings Details
8/25/2014Q414($0.12)($0.13)$1.20 million$1.20 millionViewN/AView Earnings Details
5/7/2014($0.11)($0.11)ViewN/AView Earnings Details
2/10/2014Q214($0.10)($0.10)$1.20 million$1.20 millionViewN/AView Earnings Details
8/22/2013Q4 2013($0.12)($0.09)$0.81 million$1.40 millionViewN/AView Earnings Details
5/8/2013Q3 2013($0.10)$0.11$0.97 million$1.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Immunomedics (NASDAQ:IMMU)
Current Year EPS Consensus Estimate: $-0.61 EPS
Next Year EPS Consensus Estimate: $0.02 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.13)($0.13)($0.13)
Q1 20171($0.12)($0.12)($0.12)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.05)($0.05)($0.05)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Immunomedics (NASDAQ:IMMU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Immunomedics (NASDAQ:IMMU)
Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 48.83%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2016Don C StarkDirectorSell9,900$2.97$29,403.00View SEC Filing  
8/23/2016Mary E PaetzoldDirectorSell15,000$2.98$44,700.00View SEC Filing  
6/13/2016Cynthia L GoldenbergCEOSell371,990$3.03$1,127,129.70View SEC Filing  
6/8/2016Cynthia L GoldenbergCEOSell41,441$3.62$150,016.42View SEC Filing  
6/8/2016David M GoldenbergChairmanSell353,010$3.88$1,369,678.80View SEC Filing  
6/7/2016Cynthia L GoldenbergCEOSell4,600$4.01$18,446.00View SEC Filing  
6/7/2016David M GoldenbergChairmanSell12,300$3.98$48,954.00View SEC Filing  
6/6/2016Cynthia L GoldenbergCEOSell63,959$4.09$261,592.31View SEC Filing  
6/6/2016David M GoldenbergChairmanSell110,322$4.09$451,216.98View SEC Filing  
6/15/2015David M GoldenbergChairmanSell210,991$4.08$860,843.28View SEC Filing  
6/12/2015Brian A MarkisonDirectorSell5,564$4.22$23,480.08View SEC Filing  
6/12/2015David M GoldenbergChairmanSell359,653$4.32$1,553,700.96View SEC Filing  
6/9/2015Mary E PaetzoldDirectorSell4,677$4.60$21,514.20View SEC Filing  
6/5/2015Don C StarkDirectorSell5,732$4.14$23,730.48View SEC Filing  
12/11/2014Mary E PaetzoldDirectorSell10,000$4.71$47,100.00View SEC Filing  
12/9/2014Don C StarkDirectorSell5,500$4.51$24,805.00View SEC Filing  
9/13/2013Don StarkDirectorSell10,000$6.08$60,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Immunomedics (NASDAQ:IMMU)
DateHeadline
4-traders.com logoImmunomedics, Inc. (NASDAQ:IMMU) Files An 8-K Regulation FD Disclosure (NASDAQ:IMMU)
www.4-traders.com - February 20 at 5:20 PM
News IconA Keen Look At The Chart For Immunomedics, Inc. (IMMU) - NY Stock News (NASDAQ:IMMU)
nystocknews.com - February 20 at 10:38 AM
News IconAnalysts See Compelling Value in: Immunomedics, Inc. (NASDAQ ... - Post Registrar (NASDAQ:IMMU)
postregistrar.com - February 20 at 10:38 AM
News IconABR Of Immunomedics, Inc. (NASDAQ:IMMU) Stock At 2 - Stock Observer (NASDAQ:IMMU)
www.thestockobserver.com - February 18 at 10:56 AM
finance.yahoo.com logoImmunomedics Presents Updated Results With Sacituzumab Govitecan (IMMU-132) in Heavily-Pretreated Patients ... - Yahoo Finance (NASDAQ:IMMU)
finance.yahoo.com - February 18 at 10:56 AM
streetinsider.com logoImmunomedics (IMMU) Presents Updated Results With IMMU-132 in Heavily-Pretreated Patients With Metastatic UC (NASDAQ:IMMU)
www.streetinsider.com - February 17 at 5:32 PM
marketexclusive.com logoImmunomedics,Inc. (NASDAQ:IMMU) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:IMMU)
marketexclusive.com - February 17 at 5:32 PM
4-traders.com logoIMMUNOMEDICS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) (NASDAQ:IMMU)
www.4-traders.com - February 17 at 5:32 PM
investopedia.com logoVenBio Blocks Immunomedics Deal (IMMU, SGEN) (NASDAQ:IMMU)
www.investopedia.com - February 17 at 5:32 PM
News IconImmunomedics Inc – Product Pipeline Review – Pharmaceutical 2017 (NASDAQ:IMMU)
www.medgadget.com - February 17 at 5:32 PM
us.rd.yahoo.com logoVenBio Tries to Block Immunomedics Cancer Deal (NASDAQ:IMMU)
us.rd.yahoo.com - February 17 at 5:32 PM
us.rd.yahoo.com logoImmunomedics Presents Updated Results With Sacituzumab Govitecan (IMMU-132) in Heavily-Pretreated Patients With Metastatic Urothelial Cancer (NASDAQ:IMMU)
us.rd.yahoo.com - February 17 at 5:32 PM
biz.yahoo.com logoIMMUNOMEDICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:IMMU)
biz.yahoo.com - February 17 at 5:32 PM
News Icon"Immunomedics Inc - Product Pipeline Review - 2016" now available at Fast Market Research (NASDAQ:IMMU)
reports.pr-inside.com - February 16 at 9:46 PM
law360.com logoImmunomedics Will Turn Over Sale Documents To Investors (NASDAQ:IMMU)
www.law360.com - February 16 at 9:46 PM
law360.com logoImmunomedics Will Turn Over Sale Documents To Investors (NASDAQ:IMMU)
www.law360.com - February 16 at 9:46 PM
biz.yahoo.com logoIMMUNOMEDICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti (NASDAQ:IMMU)
biz.yahoo.com - February 16 at 9:46 PM
biz.yahoo.com logoIMMUNOMEDICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti (NASDAQ:IMMU)
biz.yahoo.com - February 16 at 9:46 PM
biz.yahoo.com logoIMMUNOMEDICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti (NASDAQ:IMMU)
biz.yahoo.com - February 16 at 9:46 PM
capitalcube.com logoImmunomedics, Inc. :IMMU-US: Earnings Analysis: Q2, 2017 By the Numbers : February 15, 2017 (NASDAQ:IMMU)
us.rd.yahoo.com - February 16 at 4:45 PM
us.rd.yahoo.com logoIMMUNOMEDICS INC Financials (NASDAQ:IMMU)
us.rd.yahoo.com - February 16 at 4:45 PM
us.rd.yahoo.com logoImmunomedics Sends Letter to Stockholders Highlighting Value Creating Global Licensing Agreement, Underscoring Fulfillment of Promise to Stockholders (NASDAQ:IMMU)
us.rd.yahoo.com - February 16 at 4:45 PM
biz.yahoo.com logoIMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:IMMU)
biz.yahoo.com - February 15 at 9:02 PM
reuters.com logoBRIEF-Immunomedics issued statement in response to lawsuit filed on Feb. 13 by Venbio Select Advisor (NASDAQ:IMMU)
www.reuters.com - February 15 at 5:19 AM
News IconImmunomedics, Inc. (NASDAQ:IMMU) Refers To The VenBio Lawsuit Against The Company As Baseless And Shameful (NASDAQ:IMMU)
www.financialstrend.com - February 15 at 5:19 AM
law360.com logoImmunomedics Investor Says Board Avoiding Director Election (NASDAQ:IMMU)
www.law360.com - February 15 at 12:15 AM
thestreet.com logoActivist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics (NASDAQ:IMMU)
us.rd.yahoo.com - February 15 at 12:15 AM
us.rd.yahoo.com logovenBio Takes Steps to Protect Rights of Immunomedics Stockholders (NASDAQ:IMMU)
us.rd.yahoo.com - February 15 at 12:15 AM
thestreet.com logoActivist Investor to Block Partnership of Immunomedics and Seattle Genetics (NASDAQ:IMMU)
us.rd.yahoo.com - February 15 at 12:15 AM
bizjournals.com logoSeattle Genetics signs $2B licensing deal with Immunomedics for cancer drug (NASDAQ:IMMU)
www.bizjournals.com - February 15 at 12:15 AM
News IconLooking at the Gauges on Immunomedics Inc. (IMMU) - BVN (NASDAQ:IMMU)
bvnewsjournal.com - February 14 at 7:15 PM
finance.yahoo.com logo4:49 pm Immunomedics responds to Venbio lawsuit, calls the suit 'baseless, selfish and shameful' (NASDAQ:IMMU)
finance.yahoo.com - February 14 at 7:15 PM
feeds.benzinga.com logoImmunomedics Comments on Baseless venBio Lawsuit (NASDAQ:IMMU)
feeds.benzinga.com - February 14 at 5:24 PM
News IconImmunomedics, Inc. (NASDAQ:IMMU) Is Running Up, More To Come? - Insider Financial (NASDAQ:IMMU)
www.insiderfinancial.com - February 14 at 5:00 AM
fool.com logoSeattle Genetics Earnings: Waiting on ECHELON (NASDAQ:IMMU)
www.fool.com - February 14 at 5:00 AM
News IconStocks News Update: Advanced Micro Devices, Inc. (NASDAQ:AMD), Immunomedics Inc. (NASDAQ:IMMU) - The Newburgh Press (NASDAQ:IMMU)
newburghpress.com - February 13 at 6:56 PM
marketexclusive.com logoHere's Our Take On The Immunomedics, Inc. (NASDAQ:IMMU) Deal - Market Exclusive (NASDAQ:IMMU)
marketexclusive.com - February 13 at 6:56 PM
News IconWhy Immunomedics' $2 Billion Deal With Seattle Genetics Has venBio Ticked Off and Red-Faced (NASDAQ:IMMU)
www.biospace.com - February 13 at 11:14 AM
us.rd.yahoo.com logoEdited Transcript of IMMU earnings conference call or presentation 10-Feb-17 1:00pm GMT (NASDAQ:IMMU)
us.rd.yahoo.com - February 13 at 11:14 AM
News IconHere’s Our Take On The Immunomedics, Inc. (IMMU) Deal (NASDAQ:IMMU)
feedproxy.google.com - February 13 at 11:03 AM
rttnews.com logoICPT Catches Investors' Eyes, TCON Abuzz, IMMU Inks $2Bln Deal With SGEN (NASDAQ:IMMU)
www.rttnews.com - February 12 at 10:46 PM
fool.com logoWill Seattle Genetics' Deal With Immunomedics Get Scuttled? (NASDAQ:IMMU)
www.fool.com - February 12 at 5:45 PM
News IconImmunomedics in up to US$2 billion licensing deal with Seattle Genetics (NASDAQ:IMMU)
www.channelnewsasia.com - February 11 at 5:57 PM
benzinga.com logoShkreli: I'd Short Immunomedics On The Bounce (NASDAQ:IMMU)
www.benzinga.com - February 11 at 4:41 AM
News IconImmunomedics reaches licensing deal for key product that could be worth $2B (NASDAQ:IMMU)
www.njbiz.com - February 10 at 11:40 PM
News IconImmunomedics' $2B tie-up with Seattle Genetics offers escape hatch (NASDAQ:IMMU)
www.bioworld.com - February 10 at 11:40 PM
us.rd.yahoo.com logo6:50 am Immunomedics enters into exclusive global licensing agreement with Seattle Genetics (SGEN (NASDAQ:IMMU)
us.rd.yahoo.com - February 10 at 11:40 PM
News IconSeattle Genetics, Immunomedics Ink $2 Billion Tumor Drug Deal (NASDAQ:IMMU)
www.biospace.com - February 10 at 6:39 PM
schaeffersresearch.com logoYelp, Sears Holdings, Immunomedics News Today (NASDAQ:IMMU)
www.schaeffersresearch.com - February 10 at 6:39 PM
News IconBiotechs License Solid Tumor Therapy in $2.1B Deal (NASDAQ:IMMU)
sciencebusiness.technewslit.com - February 10 at 6:39 PM

Social

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

Where is Immunomedics' stock going? Where will Immunomedics' stock price be in 2017?

2 brokers have issued 1 year target prices for Immunomedics' shares. Their predictions range from $5.50 to $5.50. On average, they expect Immunomedics' share price to reach $5.50 in the next twelve months.

When will Immunomedics announce their earnings?

Immunomedics is scheduled to release their next quarterly earnings announcement on Thursday, February, 9th 2017.

Who owns Immunomedics stock?

Immunomedics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include First Light Asset Management LLC (2.15%), State Street Corp (1.52%), Arrowpoint Asset Management LLC (1.44%), FMR LLC (1.07%), State Board of Administration of Florida Retirement System (0.09%) and Metropolitan Life Insurance Co. NY (0.06%). Company insiders that own Immunomedics stock include Brian A Markison, Cynthia L Goldenberg, David M Goldenberg, Don C Stark and Mary E Paetzold.

Who bought Immunomedics stock? Who is buying Immunomedics stock?

Immunomedics' stock was bought by a variety of institutional investors in the last quarter, including Arrowpoint Asset Management LLC, First Light Asset Management LLC, State Street Corp, Two Sigma Investments LP and Metropolitan Life Insurance Co. NY.

How do I buy Immunomedics stock?

Shares of Immunomedics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Immunomedics stock cost?

One share of Immunomedics stock can currently be purchased for approximately $5.34.

Immunomedics (NASDAQ:IMMU) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Earnings History Chart

Earnings by Quarter for Immunomedics (NASDAQ:IMMU)

Dividend History Chart

Dividend Payments by Quarter for Immunomedics (NASDAQ:IMMU)

Last Updated on 2/20/2017 by MarketBeat.com Staff